Author + information
- Jason H. Rogers, MD∗ (, )
- Irwin Goldstein, MD and
- Krishna J. Rocha-Singh, MD
- ↵∗Division of Cardiovascular Medicine, University of California, Davis Medical Center, 4860 Y Street, Suite 2820, Sacramento, California 95817
We thank Dr. Ng and colleagues for their query. As stated in the manuscript, the primary feasibility endpoint of the ZEN trial was obtained at 3 months and was defined as improvement in erectile function from pre-procedure of the IIEF-6 score by ≥4 points in ≥50% of subjects. These data are presented in Table 3 in our original article (1), which is labeled “Primary and Secondary Endpoints.” The IIEF improvement presented in this table represents the IIEF-6 score as described in the methods section (although it is described as “IIEF improvement ≥4 points”). Figure 4 in our original paper (1) represents the total IIEF score as described in the figure legend. We apologize for any confusion this may have caused. The table below provides further information not formally presented in the article as to the raw IIEF-6 scores obtained pre-procedure and in follow-up.
- American College of Cardiology Foundation